[1]CurrentPatentAssignee:PFIZERINC-WO2005/75473,2005,A1Locationinpatent:Page/Pagecolumn16;22-23
[1]CurrentPatentAssignee:WISDOMPHARMACEUTICAL-CN110713488,2020,ALocationinpatent:Paragraph0015
Title: Effect of epidural and intravenous use of the neurokinin-1 (NK-1) receptor antagonist maropitant on the sevoflurane minimum alveolar concentration (MAC) in dogs.
Journal: Veterinary anaesthesia and analgesia 20120301
Title: In vivo assessment of antiemetic drugs and mechanism of lycorine-induced nausea and emesis.
Journal: Archives of toxicology 20111201
Title: Effect of maropitant, a neurokinin 1 receptor antagonist, on anesthetic requirements during noxious visceral stimulation of the ovary in dogs.
Journal: American journal of veterinary research 20111201
Title: The use of maropitant to prevent vomiting induced by epidural administration of preservative free morphine through an epidural catheter in a dog.
Journal: Veterinary anaesthesia and analgesia 20110901
Title: Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer.
Journal: PloS one 20110101
Title: Acute vomiting in cats: rational treatment selection.
Journal: Journal of feline medicine and surgery 20100301
Title: Acute pancreatitis attributed to dietary indiscretion in a female mixed breed canine.
Journal: The Canadian veterinary journal = La revue veterinaire canadienne 20100201
Title: Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs.
Journal: Journal of veterinary internal medicine 20100101
Title: Effect of refrigeration of the antiemetic Cerenia (maropitant) on pain on injection.
Journal: Veterinary therapeutics : research in applied veterinary medicine 20090101
Title: Efficacy and safety of maropitant, a selective neurokinin 1 receptor antagonist, in two randomized clinical trials for prevention of vomiting due to motion sickness in dogs.
Journal: Journal of veterinary pharmacology and therapeutics 20081201
Title: Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs.
Journal: Journal of veterinary pharmacology and therapeutics 20081201
Title: Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs.
Journal: Journal of veterinary pharmacology and therapeutics 20081201
Title: Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats.
Journal: Journal of veterinary pharmacology and therapeutics 20080601
Title: Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs.
Journal: The Veterinary record 20070929
Title: The neurokinin-1 antagonist activity of maropitant, an antiemetic drug for dogs, in a gerbil model.
Journal: Journal of veterinary pharmacology and therapeutics 20070801
Title: The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs.
Journal: Journal of veterinary pharmacology and therapeutics 20070801
Title: [New antiemetics: maropitant citrate].
Journal: Tijdschrift voor diergeneeskunde 20070515
Title: Efficacy of injectable maropitant (Cerenia) in a randomized clinical trial for prevention and treatment of cisplatin-induced emesis in dogs presented as veterinary patients.
Journal: Veterinary and comparative oncology 20070301
Title: The anti-emetic efficacy of maropitant (Cerenia) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe.
Journal: The Journal of small animal practice 20070201
Title: Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs.
Journal: American journal of veterinary research 20070101
Title: Hay Kraus BL. Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone. Vet Anaesth Analg. 2013 Jan;40(1):28-34.
Title: Lesman SP, Boucher JF, Grover GS, et al. The pharmacokinetics of maropitant citrate dosed orally to dogs at 2 mg/kg and 8 mg/kg once daily for 14 days consecutive days. J Vet Pharmacol Ther. 2012 Nov 20.
Title: Alvillar BM, Boscan P, Mama KR, et al. Effect of epidural and intravenous use of the neurokinin-1 (NK-1) receptor antagonist maropitant on the sevoflurane minimum alveolar concentration (MAC) in dogs. Vet Anaesth Analg. 2012 Mar;39(2):201-5.
Title: Ramsey DS, Kincaid K, Watkins JA et al. Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs. J Vet Pharmacol Ther. 2008 Dec;31(6):538-43. doi: 10.1111/j.1365-2885.2008.00992.x.
Title: Benchaoui HA, Cox SR, Schneider RP et al. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. J Vet Pharmacol Ther. 2007 Aug;30(4):336-44.
Title: Maropitant
